Label-Free Electrochemical Detection of the Cancer Biomarker Platelet-Derived Growth Factor Receptor in Human Serum and Cancer Cells

Overexpression of the platelet-derived growth factor receptor (PDGFR) was already associated with the loss of p53 function as cancer progresses in lung, breast, and cervical cancers. Cancer biomarker detection has faced challenges and barriers due to various limitations, including a high limit of detection, low sensitivity, time-consuming techniques, and expensive equipment. Hence, the present investigation is designed to develop a cost-effective novel biosensor based on a charge-based affinity bait molecule to detect the PDGFR, thus overcoming the limitations and challenges with an immune technique based on antigen-antibody interactions. We employed EDC-NHS coupling between poly (diallyl dimethylammonium chloride) and poly(acrylic acid) to attach the multiwall carbon nanotube surface. As a result, we performed electrochemical PDGFR conversion sensing with a dynamic range of 1-10,000 ng/mL and a detection limit of 1.5 pg/mL, which is comparable to the best current results. The biosensor also displayed good selectivity, 2.51% repeatability (RSD, n = 5), and 30 days of stability. Our study provides a pathway for the design of diagnostic interfaces in biosystems, as well as the emergence of new sensor types based on ligand-receptor interactions.

Automated summary

A cost-effective novel biosensor was developed to detect PDGFR associated with cancer progression, achieving a dynamic range of 1-10,000 ng/mL and a detection limit of 1.5 pg/mL using multiwall carbon nanotubes and electrochemical PDGFR conversion sensing. The biosensor displayed good selectivity, repeatability, and stability, providing a pathway for diagnostic interface design and potential new sensor types based on ligand-receptor interactions.